Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.

NCT05047692 is registered in ClinicalTrials.gov with Cellid Co., Ltd. as lead sponsor.

NCT NCT05047692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05047692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.
Lead sponsor
Cellid Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 9, 2021
Completion date
June 21, 2023
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19